The Disciplinary Committee of Nasdaq Stockholm has found that Clinical
Laserthermia Systems AB ("CLS" or the "Company") has breached the regulations
of Nasdaq First North (the "Rulebook") and has therefore ordered CLS to pay a
fine of 15 annual fees, corresponding to an amount of SEK 2,194,286.
The Disciplinary Committee finds that CLS has breached item 2.1 (c) and item
2.2.2 in combination with item 3.2 (a) (iv), and also item 4.1, of the Rulebook
by disclosing incorrect information about the form of employment of the
Company's CEO to the Exchange and the market in conjunction with the Company's
listing application and also thereafter. According to the Disciplinary
Committee, the Company's actions have risked damaging the public confidence in
the Exchange, Nasdaq First North and the securities market.
Given the circumstances of the case and after careful consideration, the
Disciplinary Committee finds that the sanction for the Company's abovementioned
breaches should be a fine rather than delisting. The fine should be 15 annual
fees.
A detailed description of the matter and the Disciplinary Committee's decision
is available at:
http://business.nasdaq.com/list/Rules-and-Regulations/european-surveillance/disc
iplinary-processes/decisions-and-sanctions/stockholm-2019.html
Please see the attached document for a Swedish version of the decision. An
English version of the decision will be made available as soon as possible.
For further information about this exchange notice please contact Issuer
Surveillance, telephone +46 8 405 60 00, or iss@nasdaq.com.
Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=729069© 2019 GlobeNewswire
